Tags : High bleeding risk

Medtronic Reports Results of Resolute Onyx DES in Onyx ONE

Shots: The Onyx ONE global study involves assessing of Resolute Onyx DES vs Biosensor International’s BioFreedom DCS in ~2000 high bleeding risk patients with one month of dual antiplatelet therapy (DAPT) The Onyx ONE global study results: met its 1EPs of cardiac death, MI & ST @1yr. showing non-inferiority to comparator stent; acute performance with […]Read More

Medtronic Announces Onset of Onyx ONE Clear study in High

Shots: Onyx ONE Clear study will assess one-month DAPT in high bleeding risk patients implanted with the Resolute Onyx DES in the US and Japan evaluating its safety i.e. risk of cardiac death, heart attack and stent thrombosis Onyx ONE Clear is similar to Onyx ONE Global Study, involving administration of (aspirin + an anti-clotting […]Read More